Item 2.02. Results of Operations and Financial Condition.

On January 5, 2023, AnaptysBio, Inc. ("AnaptysBio") issued a press release (the "Press Release") announcing certain preliminary, unaudited financial information, including that AnaptysBio expects to report that it had cash and cash equivalents and investments of greater than $575 million as of December 31, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

AnaptysBio's audited financial statements for the fiscal year ended December 31, 2022 are not yet available. Accordingly, the preliminary financial information included in the Press Release is an estimate subject to the completion of AnaptysBio's financial closing procedures and any adjustments that may result from the completion of the audit of AnaptysBio's financial statements. The preliminary financial information may differ materially from the actual results that will be reflected in AnaptysBio's audited financial statements when they are completed and publicly disclosed. Additional information and disclosures would be required for a more complete understanding of AnaptysBio's financial position and results of operations as of December 31, 2022.

The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by AnaptysBio with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD.

AnaptysBio is furnishing the Press Release, a full copy of which is attached hereto as Exhibit 99.1.

On January 5, 2023, AnaptysBio updated its corporate investor presentation, a full copy of which is attached hereto as Exhibit 99.2.

The information in this item 7.01, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit Number            Exhibit Title or Description
  99.1                    Press release issued by AnaptysBio, Inc. announcing portfolio update,
                          dated January 5, 2023.
  99.2                    AnaptysBio Corporate Overview January 2023.
104                       Cover Page Interactive Data File (the cover page XBRL tags are embedded
                          within the inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses